Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same author

A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2004
Same author

A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer.

Clinical lung cancer·2004
Same author

Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2002
Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026
Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026
Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026
Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

[Editorial: Cell kinetics and chemotherapy]

A M Mauer

    Haematologica
    |December 1, 1975
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Modeling Chemotherapy Resistant Leukemia In Vitro
    08:41

    Modeling Chemotherapy Resistant Leukemia In Vitro

    Published on: February 9, 2016

    Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
    06:00

    Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

    Published on: May 14, 2016

    Related Experiment Videos

    Last Updated: Jun 17, 2026

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
    09:19

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

    Published on: February 6, 2015

    Modeling Chemotherapy Resistant Leukemia In Vitro
    08:41

    Modeling Chemotherapy Resistant Leukemia In Vitro

    Published on: February 9, 2016

    Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
    06:00

    Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

    Published on: May 14, 2016